Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 1/20 | 0.66 |
| ▸ | MEN1 | O00255 | 2/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.65 |
| ▸ | POLB | P06746 | 1/20 | 0.65 |
| ▸ | MAPT | P10636 | 7/20 | 0.65 |
| ▸ | TP53 | P04637 | 3/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.57 |
| ▸ | USP2 | O75604 | 2/20 | 0.57 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.57 |
| ▸ | CASP1 | P29466 | 1/20 | 0.57 |
| ▸ | CASP7 | P55210 | 1/20 | 0.57 |
| ▸ | HPGD | P15428 | 6/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13964421 | 0.92 | CNR2 (0.69) | CNR2MEN1KMT2APOLBMAPT | |
| SCHEMBL16562060 | 0.87 | MAPT (0.74) | CNR2MEN1KMT2APOLBMAPT | |
| SCHEMBL3914153 | 0.81 | MEN1 (0.66) | CNR2MEN1KMT2APOLBMAPT | |
| SCHEMBL7892222 | 0.81 | MAPT (0.84) | CNR2MAPTTP53ALDH1A1KDM4E | |
| SCHEMBL3914054 | 0.80 | MAPT (0.82) | CNR2MEN1KMT2AMAPTTP53 | |
| SCHEMBL3917114 | 0.80 | MAPT (0.82) | CNR2MAPTTP53ALDH1A1KDM4E | |
| SCHEMBL3923796 | 0.79 | MAPT (0.98) | CNR2MEN1KMT2APOLBMAPT | |
| SCHEMBL16562058 | 0.79 | MAPT (0.80) | CNR2MEN1KMT2AMAPTTP53 | |
| SCHEMBL21247199 | 0.79 | MAPT (1.00) | CNR2POLBMAPTTP53ALDH1A1 | |
| SCHEMBL3811334 | 0.79 | MAPT (0.63) | CNR2MEN1KMT2APOLBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10898516-B2 | Compositions and methods of treating diabetic retinopathy | CASE WESTERN UNIVERSITY (US) | 2021-01-26 | — | — | US | disclosed |
| US-10568851-B2 | Compounds and methods of treating ocular disorders | CASE WESTERN RESERVE UNIVERSITY (US) | 2020-02-25 | — | — | US | disclosed |
| US-10426773-B2 | Systems pharmacology for treating ocular disorders | CASE WESTERN UNIVERSITY (US) | 2019-10-01 | — | — | US | disclosed |
| EP-2509596-B1 | GAMMA AMINOACIDS FOR TREATING OCULAR DISORDERS | UNIV CASE WESTERN RESERVE (US) | 2019-08-28 | — | — | EP | disclosed |
| US-20190255102-A1 | COMPOSITIONS AND METHODS OF TREATING DIABETIC RETINOPATHY | CASE WESTERN UNIVERSITY | 2019-08-22 | — | — | US | disclosed |
| US-10272106-B2 | Compositions and methods of treating diabetic retinopathy | CASE WESTERN RESERVE UNIVERSITY (US) | 2019-04-30 | — | — | US | disclosed |
| US-20190099420-A1 | SYSTEMS PHARMACOLOGY FOR TREATING OCULAR DISORDERS | CASE WESTERN UNIVERSITY | 2019-04-04 | — | — | US | disclosed |
| US-10208049-B2 | Compounds and methods of treating ocular disorders | CASE WESTERN RESERVE UNIVERSITY (US) | 2019-02-19 | — | — | US | disclosed |
| US-10117868-B2 | Systems pharmacology for treating ocular disorders | CASE WESTERN RESERVE UNIVERSITY (US) | 2018-11-06 | — | — | US | disclosed |
| US-20180134714-A1 | COMPOUNDS AND METHODS OF TREATING OCULAR DISORDERS | CASE WESTERN RESERVE UNIVERSITY | 2018-05-17 | — | — | US | disclosed |
| WO-2015187942-A1 | COMPOSITIONS AND METHODS OF TREATING DIABETIC RETINOPATHY | CASE WESTERN RESERVE UNIVERSITY (US) | 2015-12-10 | — | — | WO | disclosed |
| US-20140357611-A1 | COMPOUNDS AND METHODS OF TREATING OCULAR DISORDERS | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR NIH | 2014-12-04 | — | — | US | disclosed |
| US-20140235604-A1 | COMPOUNDS AND METHODS OF TREATING OCULAR DISORDERS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2014-08-21 | — | — | US | disclosed |
| US-20140235562-A1 | COMPOUNDS AND METHODS OF TREATING OCULAR DISORDERS | CASE WESTERN RESERVE UNIVERSITY | 2014-08-21 | — | — | US | disclosed |
| US-8722669-B2 | Compounds and methods of treating ocular disorders | CASE WESTERN RESERVE UNIVERSITY (US) | 2014-05-13 | — | — | US | disclosed |
| US-8507546-B2 | Use of inhibitors of scavenger receptor class proteins for the treatment of infectious diseases | INSTITUTO DE MEDICINA MOLECULAR, FACULDADE DE MEDICINA DA UNIVERSIDADE DE LISBOA (PT) | 2013-08-13 | — | — | US | disclosed |
| WO-2013063269-A2 | COMPOUNDS AND METHODS OF TREATING OCULAR DISORDERS | CASE WESTERN RESERVE UNIVERSITY (US) | 2013-05-02 | — | — | WO | disclosed |
| US-20120295895-A1 | COMPOUNDS AND METHODS OF TREATING OCULAR DISORDERS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2012-11-22 | — | — | US | disclosed |
| EP-2509596-A2 | COMPOUNDS AND METHODS OF TREATING OCULAR DISORDERS | Case Western Reserve University (US) | 2012-10-17 | — | — | EP | disclosed |
| WO-2011071995-A2 | COMPOUNDS AND METHODS OF TREATING OCULAR DISORDERS | CASE WESTERN RESERVE UNIVERSITY (US) | 2011-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140235562-A1 | COMPOUNDS AND METHODS OF TREATING OCULAR DISORDERS | ALDH1A2, TXNRD2, TXNRD1 | CNR2 871/4885MEN1 4699/4885KMT2A 4342/4885 |
| US-10426773-B2 | Systems pharmacology for treating ocular disorders | GRK1, MTNR1A, MTNR1B | CNR2 54/4885MEN1 2477/4885KMT2A 4427/4885 |
| US-20190255102-A1 | COMPOSITIONS AND METHODS OF TREATING DIABETIC RETINOPATHY | GPR119, ARRB1, GRK1 | CNR2 199/4885MEN1 4875/4885KMT2A 4662/4885 |
| US-10272106-B2 | Compositions and methods of treating diabetic retinopathy | GPR119, ARRB1, GRK1 | CNR2 199/4885MEN1 4875/4885KMT2A 4662/4885 |
| US-20190099420-A1 | SYSTEMS PHARMACOLOGY FOR TREATING OCULAR DISORDERS | GRK1, MTNR1A, MTNR1B | CNR2 54/4885MEN1 2477/4885KMT2A 4427/4885 |
| US-10117868-B2 | Systems pharmacology for treating ocular disorders | GRK1, MTNR1A, MTNR1B | CNR2 54/4885MEN1 2477/4885KMT2A 4427/4885 |
| US-20120295895-A1 | COMPOUNDS AND METHODS OF TREATING OCULAR DISORDERS | ALDH1A2, NR2E3, LRAT | CNR2 103/4885MEN1 1023/4885KMT2A 2643/4885 |
| US-10568851-B2 | Compounds and methods of treating ocular disorders | ALDH1A2, TXNRD2, TXNRD1 | CNR2 871/4885MEN1 4699/4885KMT2A 4342/4885 |
| US-20140357611-A1 | COMPOUNDS AND METHODS OF TREATING OCULAR DISORDERS | ALDH1A2, TYR, HRH2 | CNR2 51/4885MEN1 546/4885KMT2A 1771/4885 |
| US-20180134714-A1 | COMPOUNDS AND METHODS OF TREATING OCULAR DISORDERS | ALDH1A2, NR2E3, LRAT | CNR2 103/4885MEN1 1023/4885KMT2A 2643/4885 |
| US-20140235604-A1 | COMPOUNDS AND METHODS OF TREATING OCULAR DISORDERS | ALDH1A2, NR2E3, LRAT | CNR2 103/4885MEN1 1023/4885KMT2A 2643/4885 |
| US-10208049-B2 | Compounds and methods of treating ocular disorders | ALDH1A2, NR2E3, LRAT | CNR2 103/4885MEN1 1023/4885KMT2A 2643/4885 |
| US-10898516-B2 | Compositions and methods of treating diabetic retinopathy | GPR119, ARRB1, GRK1 | CNR2 199/4885MEN1 4875/4885KMT2A 4662/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.